Investor Presentation

Ref: ADL/SE/2026-27/59 November 3, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sub: Q2 & H1 FY27 Investor Presentation Please find attached herewith Q2 & H1 FY27 Investor Presentation of the Company. Kindly take the same on record. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Investor Presentation November 2026 Aarti Drugs Limited A Stronger Foundation. A Better Future. Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Aarti Drugs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. 01 Q2 & H1 FY27 Business & Financial Highlights 02 Company & Business Overview Table of Contents 25 03 Industry Overview 04 Key Strengths & Growth Drivers Historical Financial Performance Q2 & H1 FY27 Business & Financial Highlights Q2 & H1 FY27 Consolidated Financial Highlights Total Revenue1 EBITDA & EBITDA Margin1 PAT & PAT Margin1 12.9% 16.6% 6.9% 10.0% +27% +63% +83% 829 138 83 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 (Rs. Crs.) Total Revenue1 EBITDA & EBITDA Margin1 PAT & PAT Margin1 12.8% 15.3% 8.0% 8.7% +23% +48% +34% 1,532 235 133 1,244 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 (Rs. Crs.) Note: 1. All figures include other income Q2 & H1 FY27 Segmental Highlights Segmental Revenue Therapeutic-wise Revenue 15.7% 8.7% 14.8% 18.2% Anti-biotic 2.4% API Anti-protozoal Formulation Anti-inflammatory Speciality Chemicals 9.3% Q2 FY27 18.1% Q2 FY27 Anti-diabetic Intermediates & Others Anti-fungal 5.6% Others 73.2% 34.1% 14.1% 10.1% 13.5% 18.2% 2.8% API Anti-biotic Formulation Anti-protozoal Speciality Chemicals Anti-inflammatory 9.7% H1 FY27 Intermediates & Others 18.3% H1 FY27 Anti-diabetic Anti-fungal 5.8% Others 72.9% 34.5% Note: 1. All figures include other income 2. Therapeutic revenue split represent split Within the API Segment; Includes sale to Pinnacle Life Sciences Consolidated Profit & Loss Statement Particulars (Rs. Crs.) Q2 FY27 Q2 FY26 YoY Q1 FY27 QoQ H1 FY27 H1 FY26 YoY Net Revenue from Operations 826.2 652.8 27% 702.8 18% 1,529.0 1,243.3 23% Other Income 2.5 0.1 0.8 3.4 0.4 Total Revenue 828.8 652.9 27% 703.6 18% 1,532.4 1,243.7 23% COGS 499.1 408.3 427.6 926.7 781.7 Gross Profit 329.7 244.6 35% 276.0 19% 605.7 462.0 31% Gross Margin (%) 39.9% 37.5% 240 bps 39.3% 60 bps 39.6% 37.2% 240 bps Employee Expenses 37.1 33.1 36.5 73.6 63.9 Other Expenses 154.7 127.1 142.6 297.2 239.4 EBITDA 137.9 84.4 63% 96.9 42% 234.8 158.8 48% EBITDA Margin (%) 16.6% 12.9% 370 bps 13.8% 280 bps 15.3% 12.8% 250 bps Finance Costs 9.6 7.7 9.2 18.9 16.3 Depreciation 19.0 16.3 18.5 37.5 31.0 PBT 109.3 60.4 81% 69.2 58% 178.5 111.5 60% PBT Margin (%) 13.2% 9.3% 390 bps 9.9% 330 bps 11.7% 9.0% 270 bps Taxes 26.5 15.2 19.1 45.6 12.4 Profit After Tax 82.8 45.2 83% 50.1 65% 132.9 99.1 34% PAT Margin (%) 10.0% 6.9% 310 bps 7.1% 290 bps 8.7% 8.0% 70 bps Earnings Per Share (EPS) 9.07 4.95 5.49 14.56 10.86 Consolidated Balance Sheet Equities & Liabilities (Rs. Crs.) Sep-26 Mar-26 Assets (Rs. Crs.) Sep-26 Mar-26 Equity Non Current assets Equity Share capital 91.3 91.3 Property, Plant and Equipment 1,096.1 1,068.3 Other Equity 1,590.3 1,457.6 Capital work in progress 235.5 213.8 Non Controlling Interest 0.1 0.4 Intangible assets 16.2 16.4 Total Equity 1,681.7 1,549.2 Right to use assets 0.9 1.7 Financial liabilities Financial Assets (i) Borrowings 239.5 256.9 (i) Investments 27.5 27.3 (ii) Lease Liabilities 0.2 0.9 (ii) Loans 0.0 0.0 (iii) Other Financial liabilities 0.3 0.2 Deferred Tax Assets (net) 0.0 0.0 Other non current Liabilities 0.0 0.0 Other non-current assets 20.0 20.0 Deferred tax liabilities (Net) 83.9 81.3 Total Non Current Assets 1,396.3 1,347.5 Provisions 4.6 4.6 Current Assets Total Non Current Liabilities 328.4 343.8 Inventories 603.1 490.8 Financial liabilities Financial Assets (i) Borrowings 379.1 318.0 Investments 0.0 0.0 (ii) Lease Liabilities 0.8 0.9 (i) Trade receivables 905.0 829.9 (iii) Trade Payables 498.5 477.9 (ii) Cash and Bank Balances 9.9 8.8 (iv) Other financial liabilities 13.2 22.8 (iii) Other Financial Assets 15.8 15.5 Provisions 13.4 8.1 (iv) Loans 1.2 0.7 Other current liabilities 117.1 87.4 Current Tax Assets 0.0 0.0 Current tax liabilities (Net) 21.5 7.1 Other current assets 122.2 122.1 Total Current Liabilities 1,043.6 922.3 Total Current Assets 1,657.4 1,467.8 Total Equity and Liabilities 3,053.7 2,815.3 Total Assets 3,053.7 2,815.3 Consolidated Cash Flow Statement Particulars (Rs. Crore) Sep-26 Sep-25 Net Profit before Tax and Extraordinary items 178.5 111.5 Adjustments for: Non-Cash Items / Other Investment or Financial Items 55.9 49.6 Operating profit before working capital changes 234.4 161.1 Changes in working capital -140.3 -9.0 Cash generated from Operations 94.0 152.1 Direct taxes paid (net of refund) -28.3 0.2 Net Cash from Operating Activities 65.7 152.4 Net Cash from Investing Activities -90.2 -94.1 Net Cash from Financing Activities 25.7 -56.2 Net Increase / (Decrease) in Cash and Cash equivalents 1.2 2.1 Add: Cash & Cash equivalents at the beginning of the period 7.3 4.6 Cash & Cash equivalents at the end of the period 8.5 6.7 Management Commentary Commenting on the r [Showing first 8,000 characters — download PDF for full document]